Lexicon Pharmaceuticals (LXRX) Total Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Total Liabilities data on file, last reported at $66.0 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 62.23% year-over-year to $66.0 million in Q1 2026; TTM through Mar 2026 was $66.0 million, a 62.23% decrease from a year earlier, with the FY2025 full-year figure at $77.4 million, down 49.2% from the prior year.
• Total Liabilities for Q1 2026 stood at $66.0 million, down from $77.4 million in the prior quarter.
• Over the last five years, Total Liabilities for LXRX reached as high as $174.6 million in Q1 2025 and fell as low as $41.5 million in Q2 2022.
• Historically, Total Liabilities has averaged $102.6 million across 5 years, with a median of $96.1 million in 2025.
• Across the five-year window, Total Liabilities surged 231.02% in 2022 and tumbled 62.23% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $77.2 million in 2022, then surged by 76.64% to $136.3 million in 2023, then advanced by 11.85% to $152.5 million in 2024, then plunged by 49.2% to $77.4 million in 2025, then fell by 14.83% to $66.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $66.0 million in Q1 2026, $77.4 million in Q4 2025, and $85.8 million in Q3 2025.